Surrozen (SRZN) Net Income towards Common Stockholders (2020 - 2026)

Surrozen (SRZN) recorded quarterly Net Income towards Common Stockholders of -$9.5 million in Q1 2026, up 19.47% quarter-over-quarter from -$11.9 million in Q4 2025, and down 3.12% on a YoY basis from -$9.9 million in Q1 2025.

Surrozen (SRZN) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Surrozen's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$9.5 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 3.12% year-over-year to -$9.5 million; the TTM figure through Mar 2026 stood at -$71.2 million (down 61.32% YoY), while the FY2025 annual figure was -$39.1 million, down 63.85% from the prior year.
  • Net Income towards Common Stockholders was -$9.5 million for Q1 2026 at Surrozen, up from -$11.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $21.8 million in Q2 2025 to a low of -$71.6 million in Q3 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$12.4 million across 5 years, with a median of -$9.7 million in 2023.
  • Biggest YoY gain for Net Income towards Common Stockholders was 186.33% in 2025; the steepest drop was 4896.03% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$1.7 million in 2022, then plunged by 443.66% to -$9.2 million in 2023, then climbed by 10.96% to -$8.2 million in 2024, then slumped by 44.44% to -$11.9 million in 2025, then grew by 19.47% to -$9.5 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$9.5 million (Q1 2026), -$11.9 million (Q4 2025), and -$71.6 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -26.94 Mn
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -13.56 Mn
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn 2.50 Mn
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -14.46 Mn
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -3.63 Mn
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 1.03 Bn
9 Abivax 94.37 Bn 94.37 Bn - -56.48 Mn
10 Surrozen 225,877.86 -106.68 Mn - -9.54 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.54 Mn
Dec 31, 2025 -11.85 Mn
Sep 30, 2025 -71.64 Mn
Jun 30, 2025 21.81 Mn
Mar 31, 2025 -9.26 Mn
Dec 31, 2024 -8.21 Mn
Sep 30, 2024 -1.43 Mn
Jun 30, 2024 -25.26 Mn
Mar 31, 2024 -8.75 Mn
Dec 31, 2023 -9.22 Mn
Sep 30, 2023 -10.53 Mn
Jun 30, 2023 -9.65 Mn
Mar 31, 2023 -14.05 Mn
Dec 31, 2022 -1.70 Mn
Sep 30, 2022 -13.41 Mn
Jun 30, 2022 -14.01 Mn
Mar 31, 2022 -14.44 Mn
Dec 31, 2021 -14.95 Mn
Sep 30, 2021 -13.69 Mn
Jun 30, 2021 -12.65 Mn